All articles tagged with #hyperglycosylation
A Nature Metabolism study of UF Health records (24k dementia, 41k MCI) links glucosamine use to 25% higher five-year mortality and faster progression from MCI to Alzheimer's; mouse experiments suggest a brain sugar-processing mechanism, with glucosamine worsening memory and enzyme blockers improving symptoms. The authors warn this shows association, not causation, and urge further trials.
Nature Metabolism identifies hyperglycosylation as a driving metabolic factor in Alzheimer's disease, caused by increased glycan biosynthesis rather than reduced degradation. Across human AD brains and mouse models, elevated N-glycan production correlates with disease regions and severity; reducing glycosylation via PGM3 knockdown or OST inhibition improves cognitive outcomes in mice, while glucosamine supplementation raises brain glycans and worsens social memory. Real-world data also associate glucosamine use with accelerated progression and higher mortality in dementia cohorts. The findings propose glycan metabolism as an actionable therapeutic target and prompt clinical trials to assess glucosamine safety in dementia populations.